Drug Trial Radar · NCT07093970
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
343
Planned (sponsor's estimate)
Start
Jul 24, 2024
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Lepu Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 17 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG006A in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
MRG006ADrug
Administrated intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) - Phase ITime frame: Baseline to the end of the first treatment cycle (each cycle is 21 days).
- Recommended Phase II Dose (RP2D) - Phase ITime frame: Baseline to study completion (up to 24 months).
- Adverse Events (AEs) - Phase ITime frame: Baseline to 30 days after the last dose of study treatment.
- Serious Adverse Events (SAEs) - Phase ITime frame: Baseline to 30 days after the last dose of study treatment.
- Objective Response Rate (ORR)- Phase IITime frame: Baseline to study completion (up to 24 months).
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.